Skip to main content
Top
Published in: Orphanet Journal of Rare Diseases 1/2019

Open Access 01-12-2019 | Wilson's Disease | Research

Social and demographic characteristics of a Polish cohort with Wilson disease and the impact of treatment persistence

Authors: Wojciech Maselbas, Tomasz Litwin, Anna Czlonkowska

Published in: Orphanet Journal of Rare Diseases | Issue 1/2019

Login to get access

Abstract

Background

Wilson disease (WD) is a genetic disorder involving impaired copper metabolism, which presents with hepatic, neurological, and/or psychiatric manifestations. WD requires lifelong pharmacotherapy and treatment persistence may be problematic. We studied social characteristics, education, and work-related activities and how they are affected by WD symptoms and treatment persistence.

Methods

In a cross-sectional study, data on demographic characteristics, achieved education level, household and marital status, plus a primary source of income were collected from 202 Polish subjects (mean ± standard deviation age of 36.4 ± 9.9 years at assessment) with WD.

Results

Overall, WD appeared to have a negative impact on achieved level of education and influenced the ability to work as compared with the general Polish population. Patients with neurological manifestations less often achieved upper-secondary/post-secondary or higher education compared with those with hepatic manifestations (65.5% vs. 83.6%; p = 0.003). They also significantly less frequently stated salary (19.6% vs. 56.2%; p < 0.0001) as the primary income and more often were on disability pension (53.3% vs. 26.0%; p = 0.0003). The percentage of married patients with WD appeared lower than in the general population (47.0% vs. 54.6%), although the difference was not significant (p = 0.2). The 27.6% of patients who were non-persistent with WD treatment less frequently achieved upper/post-secondary or higher education compared with persistent patients (66.0% vs. 76.3%; NS) and their primary source of outcome was significantly less often a salary (18.9% vs. 40.3%; p = 0.001).

Conclusions

Neurological manifestations had an adverse effect on education level and work ability. Treatment non-persistence had a further negative impact regardless of the disease form. Patients with WD should receive appropriate treatment, with the need for persistence emphasized and monitored to avoid a detrimental effect on their lives.
Literature
1.
go back to reference Ala A, Walker AP, Ashkan K, et al. Wilson’s disease. Lancet. 2007;369:397–408.CrossRef Ala A, Walker AP, Ashkan K, et al. Wilson’s disease. Lancet. 2007;369:397–408.CrossRef
2.
go back to reference Bandmann O, Weiss KH, Kaler SG. Wilson's disease and other neurological copper disorders. Lancet Neurol. 2015;14:103–13.CrossRef Bandmann O, Weiss KH, Kaler SG. Wilson's disease and other neurological copper disorders. Lancet Neurol. 2015;14:103–13.CrossRef
3.
go back to reference Coffey AJ, Durkie M, Hague S, et al. A genetic study of Wilson's disease in the United Kingdom. Brain0. 2013;136:1476–87.CrossRef Coffey AJ, Durkie M, Hague S, et al. A genetic study of Wilson's disease in the United Kingdom. Brain0. 2013;136:1476–87.CrossRef
4.
go back to reference Czlonkowska A, Tarnacka B, Litwin T, et al. Wilson’s disease – cause of mortality in 164 patients during 1992–2003 observation period. J Neurol. 2005;252:698–703.CrossRef Czlonkowska A, Tarnacka B, Litwin T, et al. Wilson’s disease – cause of mortality in 164 patients during 1992–2003 observation period. J Neurol. 2005;252:698–703.CrossRef
5.
go back to reference Brewer GJ. Zinc and tetrathiomolybdate for the treatment of Wilson’s disease and the potential efficacy of anticopper therapy in a wide variety of diseases. Metallomics. 2009;1:199–206.CrossRef Brewer GJ. Zinc and tetrathiomolybdate for the treatment of Wilson’s disease and the potential efficacy of anticopper therapy in a wide variety of diseases. Metallomics. 2009;1:199–206.CrossRef
6.
go back to reference Wiggelinkhuizen M, Tilanus ME, Bollen CW, Houwen RH. Systematic review: clinical efficacy of chelator agents and zinc in the initial treatment of Wilson disease. Aliment Pharmacol Ther. 2009;29:947–58.CrossRef Wiggelinkhuizen M, Tilanus ME, Bollen CW, Houwen RH. Systematic review: clinical efficacy of chelator agents and zinc in the initial treatment of Wilson disease. Aliment Pharmacol Ther. 2009;29:947–58.CrossRef
7.
go back to reference Czlonkowska A, Gajda J, Rodo M. Effects of long-term treatment in Wilson’s disease with d-penicillamine and zinc sulphate. J Neurol. 1996;243:269–73.CrossRef Czlonkowska A, Gajda J, Rodo M. Effects of long-term treatment in Wilson’s disease with d-penicillamine and zinc sulphate. J Neurol. 1996;243:269–73.CrossRef
8.
go back to reference Maselbas W, Chabik G, Czlonkowska A. Persistence with treatment in patients with Wilson disease. Neurol Neurochir Pol. 2010;44:260–3.CrossRef Maselbas W, Chabik G, Czlonkowska A. Persistence with treatment in patients with Wilson disease. Neurol Neurochir Pol. 2010;44:260–3.CrossRef
9.
go back to reference Lo C, Bandmann O. Epidemiology and introduction to the clinical presentation of Wilson disease. Handb Clin Neurol. 2017;142:7–17.CrossRef Lo C, Bandmann O. Epidemiology and introduction to the clinical presentation of Wilson disease. Handb Clin Neurol. 2017;142:7–17.CrossRef
10.
go back to reference Czlonkowska A, Tarnacka B, Möller JC, et al. Unified Wilson’s disease rating scale – a proposal for the neurological scoring of Wilson’s disease patients. Neurol Neurochir Pol. 2007;41:1–12.PubMed Czlonkowska A, Tarnacka B, Möller JC, et al. Unified Wilson’s disease rating scale – a proposal for the neurological scoring of Wilson’s disease patients. Neurol Neurochir Pol. 2007;41:1–12.PubMed
11.
go back to reference Litwin T, Dusek P, Szafrański T, Dzieżyc K, Członkowska A, Rybakowski JK. Psychiatric manifestations in Wilson's disease: possibilities and difficulties for treatment. Ther Adv Psychopharmacol. 2018;8:199–211.CrossRef Litwin T, Dusek P, Szafrański T, Dzieżyc K, Członkowska A, Rybakowski JK. Psychiatric manifestations in Wilson's disease: possibilities and difficulties for treatment. Ther Adv Psychopharmacol. 2018;8:199–211.CrossRef
12.
go back to reference Litwin T, Gromadzka G, Czlonkowska A. Gender differences in Wilson’s disease. J Neurol Sci. 2012;312:31–5.CrossRef Litwin T, Gromadzka G, Czlonkowska A. Gender differences in Wilson’s disease. J Neurol Sci. 2012;312:31–5.CrossRef
13.
go back to reference Członkowska A, Litwin T, Karliński M, et al. D-penicillamine versus zinc sulfate as first-line therapy for Wilson’s disease. Eur J Neurol. 2014;21:599–606.CrossRef Członkowska A, Litwin T, Karliński M, et al. D-penicillamine versus zinc sulfate as first-line therapy for Wilson’s disease. Eur J Neurol. 2014;21:599–606.CrossRef
14.
go back to reference National Census of Population and Housing 2011, Central statistical office, Warsaw 2012. National Census of Population and Housing 2011, Central statistical office, Warsaw 2012.
15.
go back to reference Carta M, Mura G, Sorbello O, Farina G, Demelia L. Quality of life and psychiatric symptoms in Wilson's disease: the relevance of bipolar disorders. Clin Pract Epidemiol Ment Health. 2012;8:102–9.CrossRef Carta M, Mura G, Sorbello O, Farina G, Demelia L. Quality of life and psychiatric symptoms in Wilson's disease: the relevance of bipolar disorders. Clin Pract Epidemiol Ment Health. 2012;8:102–9.CrossRef
16.
go back to reference Portala K, Westermark K, von Knorring L, Ekselius L. Psychopathology in treated Wilson's disease determined by means of CPRS expert and self-ratings. Acta Psychiatr Scand. 2000;101:104–9.CrossRef Portala K, Westermark K, von Knorring L, Ekselius L. Psychopathology in treated Wilson's disease determined by means of CPRS expert and self-ratings. Acta Psychiatr Scand. 2000;101:104–9.CrossRef
17.
go back to reference Machado A, Chien HF, Deguti MM, et al. Neurological manifestations in Wilson’s disease: report of 119 cases. Mov Disord. 2006;21:2192–6.CrossRef Machado A, Chien HF, Deguti MM, et al. Neurological manifestations in Wilson’s disease: report of 119 cases. Mov Disord. 2006;21:2192–6.CrossRef
18.
go back to reference Fincke BG, Miller DR, Spiro A 3rd. The interaction of patient perception of overmedication with drug compliance and side effects. J Gen Intern Med. 1998;13:182–5.CrossRef Fincke BG, Miller DR, Spiro A 3rd. The interaction of patient perception of overmedication with drug compliance and side effects. J Gen Intern Med. 1998;13:182–5.CrossRef
19.
go back to reference DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for non-compliance with medical treatment. Arch Intern Med. 2000;160:2101–7.CrossRef DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for non-compliance with medical treatment. Arch Intern Med. 2000;160:2101–7.CrossRef
20.
go back to reference Leeman E. The costs of compliance. J Am Acad Psychoanal Dyn Psychiatry. 2007;35:179–87.CrossRef Leeman E. The costs of compliance. J Am Acad Psychoanal Dyn Psychiatry. 2007;35:179–87.CrossRef
21.
go back to reference Svetel M, Pekmezovic T, Tomic A, et al. Quality of life in patients with treated and clinically stable Wilson’s disease. Mov Disord. 2011;26:1503–8.CrossRef Svetel M, Pekmezovic T, Tomic A, et al. Quality of life in patients with treated and clinically stable Wilson’s disease. Mov Disord. 2011;26:1503–8.CrossRef
22.
go back to reference Dziezyc K, Karlinski M, Litwin T, Czlonkowska A. Compliant treatment with anti-copper agents prevents clinically overt Wilson's disease in pre-symptomatic patients. Eur J Neurol. 2014;21:332–7.CrossRef Dziezyc K, Karlinski M, Litwin T, Czlonkowska A. Compliant treatment with anti-copper agents prevents clinically overt Wilson's disease in pre-symptomatic patients. Eur J Neurol. 2014;21:332–7.CrossRef
23.
go back to reference Miller NH. Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med. 1997;102:43–9.CrossRef Miller NH. Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med. 1997;102:43–9.CrossRef
Metadata
Title
Social and demographic characteristics of a Polish cohort with Wilson disease and the impact of treatment persistence
Authors
Wojciech Maselbas
Tomasz Litwin
Anna Czlonkowska
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2019
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-019-1133-2

Other articles of this Issue 1/2019

Orphanet Journal of Rare Diseases 1/2019 Go to the issue